Peptides Similar to PP405
Compare PP405 with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Minoxidil: Low - Both are topical treatments for androgenetic alopecia, but with completely different mechanisms of action
- •Finasteride: Low - Both treat androgenetic alopecia, but PP405 is topical with no hormonal mechanism while finasteride is oral and anti-androgenic
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| PP405 (current) | - | - |
| Minoxidil | Low - Both are topical treatments for androgenetic alopecia, but with completely different mechanisms of action | Minoxidil is a potassium channel opener and vasodilator that prolongs the anagen phase. PP405 is an MPC inhibitor that reactivates dormant hair follicle stem cells via metabolic reprogramming. Minoxidil has decades of clinical data and is FDA-approved. PP405 is investigational. |
| Finasteride | Low - Both treat androgenetic alopecia, but PP405 is topical with no hormonal mechanism while finasteride is oral and anti-androgenic | Finasteride inhibits 5-alpha reductase to reduce DHT, addressing the hormonal driver of male pattern baldness. PP405 targets hair follicle stem cell metabolism independent of the androgen pathway. Finasteride is FDA-approved and well-established. PP405 is investigational. |
MinoxidilLow - Both are topical treatments for androgenetic alopecia, but with completely different mechanisms of action
Differences
Minoxidil is a potassium channel opener and vasodilator that prolongs the anagen phase. PP405 is an MPC inhibitor that reactivates dormant hair follicle stem cells via metabolic reprogramming. Minoxidil has decades of clinical data and is FDA-approved. PP405 is investigational.
Advantages
Novel mechanism targeting stem cell activation rather than vasodilation, no systemic absorption detected, potential to regenerate hair in bald areas rather than just maintaining existing hair, works in both sexes
Disadvantages
Investigational with limited clinical data, not commercially available, no long-term efficacy or safety data, not yet compared head-to-head with minoxidil
FinasterideLow - Both treat androgenetic alopecia, but PP405 is topical with no hormonal mechanism while finasteride is oral and anti-androgenic
Differences
Finasteride inhibits 5-alpha reductase to reduce DHT, addressing the hormonal driver of male pattern baldness. PP405 targets hair follicle stem cell metabolism independent of the androgen pathway. Finasteride is FDA-approved and well-established. PP405 is investigational.
Advantages
No systemic absorption or hormonal side effects, applicable to women (finasteride is not), novel mechanism that may complement existing treatments, topical application
Disadvantages
Investigational with limited data, mechanism does not address the underlying androgenic cause of hair loss, no long-term data, not yet available commercially
Hair Loss Treatment Landscape#
PP405 represents a first-in-class approach to treating androgenetic alopecia by targeting hair follicle stem cell metabolism. To understand its potential place in therapy, it is useful to compare it with established and emerging treatments.
Approved Treatments#
| Treatment | Mechanism | Route | FDA Status | Key Limitation |
|---|---|---|---|---|
| Minoxidil | Vasodilator / K+ channel opener | Topical | Approved (1988) | Mainly maintains existing hair |
| Finasteride | 5-alpha reductase inhibitor | Oral | Approved (1997) | Sexual side effects, men only |
| Dutasteride | Dual 5-alpha reductase inhibitor | Oral | Off-label (approved for BPH) | Sexual side effects, men only |
| Low-level laser therapy | Photobiomodulation | Device | FDA-cleared | Modest efficacy |
Investigational Treatments#
| Treatment | Mechanism | Route | Status |
|---|---|---|---|
| PP405 | MPC inhibitor (stem cell activation) | Topical | Phase 2a completed |
| Clascoterone | Topical androgen receptor antagonist | Topical | FDA-approved for acne; Phase 2 for AGA |
| Pyrilutamide | Topical androgen receptor antagonist | Topical | Phase 3 (China) |
| JAK inhibitors | JAK/STAT pathway inhibition | Topical/oral | Approved for alopecia areata |
PP405 vs. Minoxidil#
Minoxidil has been the standard topical treatment for androgenetic alopecia since 1988. Key differences:
- Mechanism: Minoxidil acts as a vasodilator and potassium channel opener, prolonging the anagen phase. PP405 reactivates dormant follicle stem cells through metabolic reprogramming.
- Systemic exposure: Minoxidil has measurable systemic absorption and can cause cardiovascular effects. PP405 shows no detectable systemic absorption.
- Onset of action: Minoxidil typically requires 3-6 months for visible results. PP405 showed measurable effects at 8 weeks in Phase 2a.
- Type of regrowth: Minoxidil primarily maintains existing hair and may convert vellus hairs to terminal hairs. PP405 showed evidence of new hair growth in previously bald areas.
PP405 vs. Finasteride#
Finasteride remains the most effective single agent for male androgenetic alopecia. Key differences:
- Mechanism: Finasteride blocks the conversion of testosterone to DHT, the primary hormonal driver of male pattern baldness. PP405 does not interact with the androgen pathway.
- Gender applicability: Finasteride is only approved for men and is contraindicated in pregnancy. PP405 was tested in both men and women.
- Safety: Finasteride carries risks of sexual dysfunction, depression, and post-finasteride syndrome (controversial). PP405 has no reported systemic side effects.
- Complementary potential: Because PP405 and finasteride have completely different mechanisms, they could potentially be used in combination, though this has not been studied.
Comparison Context#
PP405 belongs to the Skin category of research peptides. Comparing PP405 with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to PP405 in mechanism, indication, or therapeutic category:
PP405 vs Minoxidil#
Similarity: Low - Both are topical treatments for androgenetic alopecia, but with completely different mechanisms of action
Key Differences: Minoxidil is a potassium channel opener and vasodilator that prolongs the anagen phase. PP405 is an MPC inhibitor that reactivates dormant hair follicle stem cells via metabolic reprogramming. Minoxidil has decades of clinical data and is FDA-approved. PP405 is investigational.
Advantages of Minoxidil: Novel mechanism targeting stem cell activation rather than vasodilation, no systemic absorption detected, potential to regenerate hair in bald areas rather than just maintaining existing hair, works in both sexes
Disadvantages of Minoxidil: Investigational with limited clinical data, not commercially available, no long-term efficacy or safety data, not yet compared head-to-head with minoxidil
Researchers choosing between PP405 and Minoxidil should consider the development stage, available evidence, and specific research objectives when making their selection.
PP405 vs Finasteride#
Similarity: Low - Both treat androgenetic alopecia, but PP405 is topical with no hormonal mechanism while finasteride is oral and anti-androgenic
Key Differences: Finasteride inhibits 5-alpha reductase to reduce DHT, addressing the hormonal driver of male pattern baldness. PP405 targets hair follicle stem cell metabolism independent of the androgen pathway. Finasteride is FDA-approved and well-established. PP405 is investigational.
Advantages of Finasteride: No systemic absorption or hormonal side effects, applicable to women (finasteride is not), novel mechanism that may complement existing treatments, topical application
Disadvantages of Finasteride: Investigational with limited data, mechanism does not address the underlying androgenic cause of hair loss, no long-term data, not yet available commercially
Researchers choosing between PP405 and Finasteride should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About PP405
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer